证券日报网12月30日讯，爱迪特（301580）在接受调研者提问时表示，公司根据市场趋势和公司战略规 划，计划加大各产品线的产能，爱迪特牙科产业园明年将完成主要生产车间的建设与逐步投产。未来， 公司的产品结构将得到进一步优化，覆盖更多的客户群体，拓展更广阔的市场空间，提高整体的盈利水 平，将使公司在生产规模和盈利能力上再上新台阶。 ...

Core Insights - Dentsply International reported quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share, and down from $0.50 per share a year ago, representing an earnings surprise of -17.78% [1] - The company posted revenues of $904 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.27%, but down from $951 million year-over-year [2] - Dentsply shares have declined approximately 33.5% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.47 on revenues of $931.32 million, and for the current fiscal year, it is $1.87 on revenues of $3.65 billion [7] Estimate Revisions - The trend of estimate revisions for Dentsply was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Align Technology has raised its fourth-quarter revenue forecast and exceeded third-quarter estimates, primarily due to strong demand for dental products, resulting in a significant increase in its share price [1] Group 1: Financial Performance - The company reported better-than-expected third-quarter results, driven by robust sales in its dental product segment [1] - Align Technology has increased its revenue forecast for the fourth quarter, indicating positive momentum in its business operations [1] Group 2: Market Demand - There is a strong demand for dental products, which has been a key factor in the company's improved financial outlook [1] - The surge in demand for dental products has positively impacted Align Technology's stock performance [1]

Core Insights - Boston Scientific reported quarterly earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, and showing an increase from $0.63 per share a year ago, resulting in an earnings surprise of +5.63% [1] - The company achieved revenues of $5.07 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.94%, and up from $4.21 billion year-over-year [2] - Boston Scientific has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise of +5.63% indicates strong performance relative to expectations, with a previous quarter's surprise of +4.17% [1][2] - The company has maintained a favorable trend in estimate revisions leading up to the earnings release, contributing to a Zacks Rank 2 (Buy) for the stock [6] Future Outlook - Current consensus EPS estimate for the upcoming quarter is $0.76 on revenues of $5.16 billion, and for the current fiscal year, it is $2.98 on revenues of $19.85 billion [7] - The sustainability of stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] Industry Context - The Medical - Products industry, to which Boston Scientific belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can significantly affect stock performance [5][8]

Core Viewpoint - Envista (NVST) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to institutional investors adjusting their valuations, resulting in stock price movements [4]. Company Performance and Outlook - The recent upgrade for Envista suggests an improvement in its underlying business, which could lead to higher stock prices as investors respond positively [5][10]. - For the fiscal year ending December 2025, Envista is expected to earn $1.04 per share, with a 6% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Envista's upgrade places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Insights - Pro-Dex, Inc. (PDEX) reported quarterly earnings of $0.98 per share, significantly exceeding the Zacks Consensus Estimate of $0.47 per share, and up from $0.19 per share a year ago, representing an earnings surprise of 108.51% [1] - The company posted revenues of $17.41 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 1.62%, but up from $14.29 million year-over-year [2] - Pro-Dex shares have increased approximately 40.5% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $18.5 million, and for the current fiscal year, it is $2.30 on revenues of $67.9 million [7] - The estimate revisions trend for Pro-Dex is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which Pro-Dex belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Dentsply International (XRAY), is expected to report a year-over-year earnings decline of 31% for the quarter ended March 2025, with revenues anticipated to drop by 10.7% [9][10]